$CBLL Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.55 down -48.65% YoY
• Reported revenue of $29.34M up 29.88% YoY
• Ceribell raised full-year 2026 revenue guidance to $115M to $117M, representing approximately 29% to 31% growth over the prior year; the range excludes material contributions from neonate, pediatric, or delirium products.